Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades22
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- IN BRIEF: Faron Pharmaceuticals joins US grant for battlefield wounds
13 Aug 2024 - EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx
12 Aug 2024 - IN BRIEF: Faron Pharmaceuticals names Petri Bono as CMO
6 Aug 2024 - TRADING UPDATES: Titon warns on trading; Videndum revenue in-line
11 Jul 2024 - Faron gets positive FDA feedback on bexmarilimab study plans
11 Jul 2024 - AIM WINNERS & LOSERS: Titon falls amid subdued housing market demand
11 Jul 2024 - AIM WINNERS & LOSERS: Vast Resources touts progress across mines
4 Jun 2024 - Faron Pharma celebrates positive read-out in ongoing MDS trial
20 May 2024
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
IN BRIEF: Faron Pharmaceuticals joins US grant for battlefield wounds
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical maker - Joins consortium that has received a USD1.5 million grant fr...
EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in August so far and not separately repo...
IN BRIEF: Faron Pharmaceuticals names Petri Bono as CMO
Faron Pharmaceuticals Oy - Turku, Finland-based clinical-stage biopharmaceutical company - Names Petri Bono as the new chief medical officer with effe...
TRADING UPDATES: Titon warns on trading; Videndum revenue in-line
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Faron gets positive FDA feedback on bexmarilimab study plans
(Sharecast News) - Faron Pharmaceuticals announced positive feedback from the FDA regarding the clinical development plan for its drug candidate bexma...
AIM WINNERS & LOSERS: Titon falls amid subdued housing market demand
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.
AIM WINNERS & LOSERS: Vast Resources touts progress across mines
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Faron Pharma celebrates positive read-out in ongoing MDS trial
(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form...
Follow the stocks
